Please login to the form below

Not currently logged in

Boehringer stays ahead of the curve

Boehringer Ingelheim revealed that its performance to the end of 2007 has 'outpaced' the market for the eighth consecutive year
Boehringer Ingelheim revealed that its performance to the end of 2007 has 'outpace' the market for the eighth consecutive year.

Boehringer recorded turnover went up from $10.5bn in 2006 to almost $11bn in 2007, a rise of 8.8 per cent in local currency (3.3 per cent in euro terms).

"The fact that Boehringer successfully achieved growth of 3.6 per cent in euro terms despite these challenges highlights the excellent dynamic growth of its product portfolio," the company said in a statement.

According to Boehringer, the company overcame several challenges in 2007 including US patent expiry for its product Mobic. Net sales of the arthritis painkiller fell by $340m and needed to be offset.

Dr Alessandro Banchi, chairman of the board of managing directors for Boehringer and head of corporate board division of pharma marketing and sales, said: "We can look back once again on a successful year for Boehringer Ingelheim with continued growth in 2007. Our products are benefiting patients, our product pipeline is well equipped and our workforce is highly motivated."

The company's healthy financial position allowed for the creation of 1,400 new jobs, bringing Boehringer's employee total to 39,800, a rise of 3.6 per cent. Boehringer has, since 2003, recruited an additional 5,500 members of staff, an overall increase of 16 per cent for the four-year period.

The company came first in the 2007 Top Employers Survey conducted by the journal Science that named it as the most attractive employer in the science community in Europe and the US.

8th April 2008


Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....